Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 3, Bradley Canino from Guggenheim initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy rating and a $40 price target. The analyst noted that they liked the stock when it was trading at$3 as the market overlooked an important upcoming progression-free survival readout for its drug Ivonescimab in direct comparison to Merck’s Pembrolizumab in lung cancer. No ...